-
FDA Clears U-M Stem Cell Clinical Trial To Recruit ALS Patients
Medical writer Robin Erb continues her NSI-566/ALS trial reporting with an overview of its next phase, Phase II, which is scheduled to include 15 patients and is now approved by the FDA.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.